Target ALS, a leading organization dedicated to breaking down barriers to accelerate amyotrophic lateral sclerosis (ALS) research to find effective treatments, today announced that data from a strategic partnership with ZEPHYRx, a pioneer in remote respiratory monitoring solutions, is now available to global scientists. This collaboration will integrate data collected by ZEPHYRx with rich clinical and biological datasets from participants in the Target ALS Global Natural History Study and be freely accessible to researchers via the Target ALS Data Engine.

Morgan Scientific, an industry leader in PFT software that delivers advanced enterprise point-of-care solutions, today announced a strategic partnership with ZEPHYRx. The partnership brings ZEPHYRx’s respiratory platform together with Morgan Scientific’s ComPAS2 PFT software. This integration will enable healthcare providers to monitor their patient’s lung function at-home. The expanded remote spirometry offering is powered by ZEPHYRx’s respiratory cloud platform and enables real-time PFT data collection from patients wherever they are – like from the comfort of home.

ZEPHYRx and NIOX today announced they have partnered to integrate FeNO by NIOX® into the ZEPHYRx Respiratory Cloud Platform to advance clinical research by offering one source of truth for multiple respiratory endpoints. ZEPHYRx, a health information technology innovator, has quickly become an industry leader in respiratory monitoring solutions for hybrid clinical research. In working with sponsors, ZEPHYRx and NIOX recognized a need for a more seamless solution by integrating FeNO by NIOX® measurements into the ZEPHYRx platform. NIOX, the world leader in FeNO testing, is the partner of choice for ZEPHYRx to further expand its offering for clinical research.

EverythingALS, has initiated a new study, The Radcliff Study, with partners in the quest to find a diagnosis, treatment, and cure for ALS. EverythingALS is teaming up with Aural Analytics, FeetMe, ZEPHYRx, and a major pharmaceutical company. The Radcliff Study is a novel research-as-a-feasibility study to inform the likelihood of success for a pre-competitive collaboration focused on developing an end-to-end digital alternative for the ALSFRS-R that supports clinically meaningful outcomes tailored for use in ALS.

RxCap, Inc., cloud-based remote monitoring enablement company, and ZEPHYRx LLC, a remote respiratory monitoring solutions provider, announced that they have entered into a partnership to integrate the ZEPHYRx cloud spirometry platform with RxCap's remote monitoring platform. With this new partnership, RxCap's enterprise customers, such as providers and payers, will be able to monitor the lung function of their patients and members with serious pulmonary conditions. By partnering with RxCap, enterprises can quickly build revenue-generating RPM programs that integrate with their existing care workflows and provide seamless experiences for their patients and members.

ZEPHYRx, LLC and MIR, Medical International Research, today announced they have entered into an exclusive partnership to jointly market the ZEPHYRx Remote Respiratory Monitoring (RRM) Solution. Under the new partnership, this will be the only remote patient monitoring (RPM) solution offered by MIR in North America. ZEPHYRx, a health information technology innovator, has quickly become an industry leader in RPM solutions for respiratory health. ZEPHYRx is the largest reseller of MIR’s Spirobank® Smart Spirometer and has been working with MIR, a global leader in medical devices and software, since its inception in 2019. With MIR’s well-established customer base and highly qualified sales personnel, MIR is the partner of choice for ZEPHYRx to fuel its path of accelerating growth.